Durmus M.Turkoz A.Togal T.Koroglu A.Toprak H.I.Ersoy M.O.2024-08-042024-08-0420020265-0215https://doi.org/10.1097/00003643-200211000-00014https://hdl.handle.net/11616/90559[No abstract available]eninfo:eu-repo/semantics/closedAccessanesthetic agentbarbituric acid derivativebenzodiazepine derivativedesfluraneenfluraneferrous ionhalothanehemeinhalation anesthetic agentisofluranenitric oxideporphobilinogenporphyrinpropofolprotoporphyrinremifentanilsevofluranethiopentalacute intermittent porphyriaadultanesthesia complicationanesthesia inductionbrain diseasecase reportcesarean sectiondrug clearancedrug contraindicationdrug metabolismdrug safetyfemaleheme synthesishigh risk patienthumanletterpathogenesisporphyrin metabolismpregnancyrisk factorRemifentanil and acute intermittent porphyria [4]Letter19118398401244293810.1097/00003643-200211000-000142-s2.0-0036829493Q1